Clinical Trials Logo
  1. Home
  2. Prolactinoma
  3. NCT04106531

Validation of a Quality of Life Metric "Prolac-10" — Prolac-10  

Pituitary Tumor Clinical Trial

Official title:
Validation of a Novel Patient-Reported Quality of Life Metric "Prolac-10" for Patients Undergoing Medical Therapy for Prolactinoma

Clinical Trial Summary

This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.

Clinical Trial Description

This is a single-site validation study of a novel quality of life study for patients undergoing medical therapy for prolactinoma. Patients will be consented before starting their medical regimen and complete the "Prolac-10" questionnaire for baseline and will continued to be followed for 13-weeks into their medical care. The primary goal of this study is to validate the novel quality of life questionnaire in terms of sensitivity, repeatability, and consistency. Secondarily, we aim to validate the test-retest characteristics to further validate sensitivity, repeatability, and consistency. The Prolac-10 metric is Copyright © 2019. The Ohio State University. Modification/derivative rights reserved, all other rights available. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04106531
Study type Observational
Source Ohio State University
Contact
Status Terminated
Phase
Start date October 15, 2019
Completion date June 13, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04529356 - The TMS Treatment for Postoperative Headache in GH Tumor N/A
Completed NCT03363126 - Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma N/A
Completed NCT04212793 - Detection of PitNET Tissue During TSS Using Bevacizumab-800CW Phase 1
Recruiting NCT03309319 - A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas N/A
Recruiting NCT03719781 - Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
Recruiting NCT01556230 - Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
Recruiting NCT03132259 - Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Phase 4
Recruiting NCT01368133 - The Observational Study of Growth Hormone-secreting Pituitary Tumors N/A
Withdrawn NCT04863339 - Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery Phase 2
Terminated NCT00646308 - Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas N/A
Recruiting NCT00852501 - Characterization of Receptors in Non-functioning Pituitary Macroadenomas Phase 4
Completed NCT03465423 - Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia
Recruiting NCT03474601 - Seoul National University Pituitary Disease Cohort Study
Recruiting NCT05139277 - Evaluation of the CONVIVO System N/A
Active, not recruiting NCT03636568 - Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery) N/A
Completed NCT02813044 - Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor N/A
Recruiting NCT03973450 - Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
Active, not recruiting NCT04042753 - Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors Phase 2
Recruiting NCT04018963 - The Impact of Endoscopic Pituitary Surgery on Nasal Function
Not yet recruiting NCT04938401 - Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection